Etravirine Patent Expiration
Etravirine is used for treating HIV-1 infection in patients who are treatment-experienced and have evidence of viral replication and resistance to certain antiretroviral drugs. It was first introduced by Janssen Research And Development Llc
Etravirine Patents
Given below is the list of patents protecting Etravirine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Intelence |
US7037917 (Pediatric) | HIV replication inhibiting pyrimidines |
Jun 13, 2021
(Expired) | Janssen R And D |
| Intelence | US7037917 | HIV replication inhibiting pyrimidines |
Dec 13, 2020
(Expired) | Janssen R And D |
| Intelence |
US6878717 (Pediatric) | HIV replication inhibiting pyrimidines |
May 05, 2020
(Expired) | Janssen R And D |
| Intelence |
US8003789 (Pediatric) | HIV replication inhibiting pyrimidines |
May 01, 2020
(Expired) | Janssen R And D |
| Intelence | US6878717 | HIV replication inhibiting pyrimidines |
Nov 05, 2019
(Expired) | Janssen R And D |
| Intelence | US8003789 | HIV replication inhibiting pyrimidines |
Nov 01, 2019
(Expired) | Janssen R And D |
| Intelence |
US7887845 (Pediatric) | Antiviral compositions |
Sep 25, 2019
(Expired) | Janssen R And D |
| Intelence | US7887845 | Antiviral compositions |
Mar 25, 2019
(Expired) | Janssen R And D |
Etravirine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Etravirine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants | Janssen Sciences Ireland UC | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |